MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Simulations Plus Inc

Затворен

СекторЗдравеопазване

24.8 2.82

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

23.31

Максимум

24.85

Ключови измерители

By Trading Economics

Приходи

-637K

206K

Продажби

260K

19M

P/E

Средно за сектора

61.3

63.778

EPS

0.17

Дивидентна доходност

0.99

Марж на печалбата

1.089

Служители

243

EBITDA

-929K

126K

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+110.25% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.99%

2.39%

Следващи печалби

3.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

493M

Предишно отваряне

21.98

Предишно затваряне

24.8

Настроения в новините

By Acuity

50%

50%

180 / 386 Класиране в Healthcare

Simulations Plus Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.07.2024 г., 08:59 ч. UTC

Топ новини

These Stocks Are Moving the Most Today: Tesla, Paramount, Nvidia, Constellation Brands, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Simulations Plus Inc Прогноза

Ценова цел

By TipRanks

110.25% нагоре

12-месечна прогноза

Среден 50.67 USD  110.25%

Висок 65 USD

Нисък 37 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Simulations Plus Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

4

Купи

1

Задържане

0

Продай

Настроение

By Acuity

180 / 386 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.